Comparison of arterial and venous allograft bypass in chronic limb-threatening ischemia.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 14 02 2022
accepted: 20 09 2022
entrez: 27 10 2022
pubmed: 28 10 2022
medline: 1 11 2022
Statut: epublish

Résumé

Femoro-popliteal bypass with autologous vascular graft is a key revascularization method in chronic limb-threatening ischemia (CLTI). However, the lack of suitable autologous conduit may occur in 15-45% of the patients, necessitating the implantation of prosthetic or allogen grafts. Only little data is available on the outcome of allograft use in CLTI. Our objective were to evaluate the long term results of infrainguinal allograft bypass surgery in patients with chronic limb-threatening ischemia (CLTI) and compare the results of arterial and venous allografts. Single center, retrospective study analysing the outcomes of infrainguinal allograft bypass surgery in patients with CLTI between January 2007 and December 2017. During a 11-year period, 134 infrainguinal allograft bypasses were performed for CLTI [91 males (67.9%)]. Great saphenous vein (GSV) was implanted in 100 cases, superficial femoral artery (SFA) was implanted in 34 cases. Early postoperative complications appeared in 16.4% of cases and perioperative mortality (<30 days) was 1.4%. Primary patency at one, three and five years was 59%, 44% and 41%, respectively, while secondary patency was 60%, 45% and 41%, respectively. Primary patency of the SFA allografts was significantly higher than GSV allografts (1 year: SFA: 84% vs. GSV: 51% p = 0,001; 3 years: SFA: 76% vs. GSV: 32% p = 0,001; 5 years: SFA: 71% vs. GSV: 30% p = 0.001). Both primary and secondary patency of SFA allograft implanted in below-knee position were significantly higher than GSV bypasses (p = 0.0006; p = 0.0005, respectively). Limb salvage at one, three and five years following surgery was 74%, 64% and 62%, respectively. Long-term survival was 53% at 5 years. Allograft implantation is a suitable method for limb salvage in CLTI. The patency of arterial allograft is better than venous allograft patency, especially in below-knee position during infrainguinal allograft bypass surgery.

Identifiants

pubmed: 36301873
doi: 10.1371/journal.pone.0275628
pii: PONE-D-22-04564
pmc: PMC9612501
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0275628

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Vasc Surg. 2014 Nov;60(5):1291-1296
pubmed: 24997807
Eur J Vasc Endovasc Surg. 2017 Aug;54(2):203-211
pubmed: 28587797
J Vasc Surg. 2010 Apr;51(4):869-77
pubmed: 20347683
Ann Vasc Surg. 2019 Oct;60:379-387
pubmed: 31200034
Eur J Vasc Endovasc Surg. 2017 Nov;54(5):636-644
pubmed: 28890027
Eur J Vasc Endovasc Surg. 1997 Aug;14(2):91-5
pubmed: 9314849
J Am Coll Cardiol. 2006 Mar 21;47(6):1239-312
pubmed: 16545667
J Vasc Surg. 2018 Aug;68(2):624-633
pubmed: 29804736
J Vasc Surg. 2007 Dec;46(6):1180-90; discussion 1190
pubmed: 18154993
J Vasc Surg. 2017 Sep;66(3):844-849
pubmed: 28502546
JAMA Surg. 2016 Nov 1;151(11):1070-1077
pubmed: 27551978
Surgeon. 2022 Apr;20(2):85-93
pubmed: 33685832
J Vasc Surg. 1990 Feb;11(2):193-205; discussion 205-6
pubmed: 2299743
Arch Surg. 1980 Oct;115(10):1166-9
pubmed: 6448593
J Vasc Surg. 2003 Jun;37(6):1263-9
pubmed: 12764274
J Vasc Surg. 2015 Oct;62(4):974-83
pubmed: 26141692
J Cardiovasc Surg (Torino). 2011 Apr;52(2):169-76
pubmed: 21464818
J Vasc Surg. 2000 Mar;31(3):426-35
pubmed: 10709053
J Vasc Surg. 2016 Jul;64(1):131-139.e1
pubmed: 27345506
Nat Rev Cardiol. 2017 Mar;14(3):156-170
pubmed: 27853158
J Vasc Surg. 2012 Apr;55(4):1008-14
pubmed: 22365176
J Vasc Surg. 2016 Jul;64(1):e1-e21
pubmed: 27345516
Eur J Vasc Endovasc Surg. 2020 Mar;59(3):339-384
pubmed: 32035742
Eur J Vasc Endovasc Surg. 2000 Jul;20(1):21-4
pubmed: 10906292
Eur J Vasc Endovasc Surg. 2019 Jul;58(1S):S1-S109.e33
pubmed: 31182334
J Vasc Surg. 2013 Apr;57(4):982-9
pubmed: 23375606
J Vasc Surg. 2014 Sep;60(3):686-95.e2
pubmed: 24820900
J Vasc Surg. 2000 Oct;32(4):731-8
pubmed: 11013037
Eur J Vasc Endovasc Surg. 2019 Jun;57(6):823-831
pubmed: 31130420
J Vasc Surg. 2015 Aug;62(2):385-91
pubmed: 25943451

Auteurs

Dávid Garbaisz (D)

Department of Vascular and Endovascular Surgery, Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Péter Osztrogonácz (P)

Department of Vascular and Endovascular Surgery, Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

András Mihály Boros (AM)

Department of Cardiology, Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

László Hidi (L)

Department of Vascular and Endovascular Surgery, Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Péter Sótonyi (P)

Department of Vascular and Endovascular Surgery, Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Zoltán Szeberin (Z)

Department of Vascular and Endovascular Surgery, Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH